ETTX, NGM

Entasis Therapeutics Holdings Inc. (ETTX)

Price (as of August 1)

2.19USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

AMLX

Amylyx Pharmaceuticals, Inc.

-0.21

DBVT

DBV Technologies S.A.

-0.12

BNOX

Bionomics Limited

-0.12

AMTI

Applied Molecular Transport Inc.

-0.12

RXRX

Recursion Pharmaceuticals, Inc.

-0.12

ANEB

Anebulo Pharmaceuticals, Inc.

-0.11

ALXO

ALX Oncology Holdings Inc.

-0.11

ARTL

Artelo Biosciences, Inc.

-0.1

ANNX

Annexon, Inc.

-0.1

BWV

Blue Water Vaccines, Inc.

-0.09

Show more

Highest within Industry

Symbol Correlation

CGEN

Compugen Ltd.

0.17

BMRN

BioMarin Pharmaceutical Inc.

0.15

CYTK

Cytokinetics, Incorporated

0.15

DRMA

Dermata Therapeutics, Inc.

0.15

CALA

Calithera Biosciences, Inc.

0.15

BTAI

BioXcel Therapeutics, Inc.

0.15

ACLX

Arcellx, Inc.

0.13

CBIO

Catalyst Biosciences, Inc.

0.13

BHVN

Biohaven Pharmaceutical Holding Company Ltd.

0.12

DSGN

Design Therapeutics, Inc.

0.12

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.